Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

Related Articles by Review for PubMed (Select 18564334)

1.

Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients.

Bell DS, Bakris GL, McGill JB.

Diabetes Obes Metab. 2009 Mar;11(3):234-8. doi: 10.1111/j.1463-1326.2008.00927.x. Epub 2008 Jun 17.

PMID:
18564334
2.
3.

Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.

Talbert RL.

Heart Fail Rev. 2004 Apr;9(2):131-7. Review.

PMID:
15516861
4.

Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial.

Kveiborg B, Major-Petersen A, Christiansen B, Torp-Pedersen C.

Vasc Health Risk Manag. 2007;3(1):31-7. Review.

5.

Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol.

Kveiborg B, Christiansen B, Major-Petersen A, Torp-Pedersen C.

Am J Cardiovasc Drugs. 2006;6(4):209-17. Review.

PMID:
16913822
6.

Beta-blocker treatment of chronic heart failure: comparison of carvedilol and metoprolol.

Maack C, Elter T, Böhm M.

Congest Heart Fail. 2003 Sep-Oct;9(5):263-70. Review.

PMID:
14564145
7.

Advantages of a third-generation beta-blocker in patients with diabetes mellitus.

Bell DS.

Am J Cardiol. 2004 May 6;93(9A):49B-52B. Review.

PMID:
15144938
8.

Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.

Bauman JL, Talbert RL.

J Cardiovasc Pharmacol Ther. 2004 Jun;9(2):117-28. Review.

PMID:
15309248
9.

Carvedilol in hypertension treatment.

Stafylas PC, Sarafidis PA.

Vasc Health Risk Manag. 2008;4(1):23-30. Review.

10.

Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

McTavish D, Campoli-Richards D, Sorkin EM.

Drugs. 1993 Feb;45(2):232-58. Review.

PMID:
7681374
11.

Impact of carvedilol on the serum lipid profile.

Sharp RP, Sirajuddin R, Sharief IM.

Ann Pharmacother. 2008 Apr;42(4):564-71. doi: 10.1345/aph.1K447. Epub 2008 Mar 25. Review.

PMID:
18364407
12.
13.

Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol).

DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH.

Am J Cardiol. 2013 Mar 1;111(5):765-9. doi: 10.1016/j.amjcard.2012.11.031. Epub 2013 Jan 4. Review.

PMID:
23290925
14.

β-blockers: a review of their pharmacological and physiological diversity in hypertension.

Ripley TL, Saseen JJ.

Ann Pharmacother. 2014 Jun;48(6):723-33. doi: 10.1177/1060028013519591. Epub 2014 Mar 31. Review.

PMID:
24687542
15.
16.

Carvedilol: a third-generation β-blocker should be a first-choice β-blocker.

DiNicolantonio JJ, Hackam DG.

Expert Rev Cardiovasc Ther. 2012 Jan;10(1):13-25. doi: 10.1586/erc.11.166. Review.

PMID:
22149523
17.

Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension.

Bakris GL, Weber MA.

Rev Cardiovasc Med. 2008 Spring;9(2):96-105. Review.

PMID:
18660730
18.

Diabetes and heart failure: epidemiology, pathophysiology and management.

Desai AS, O'Gara PT.

Indian Heart J. 2005 Jul-Aug;57(4):295-303. Review. No abstract available.

PMID:
16350674
19.

Carvedilol for hypertension.

[No authors listed]

Drug Ther Bull. 1995 May;33(5):39-40. Review. No abstract available.

PMID:
7587995
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk